Acute Myelogenous Leukemia - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Acute Myelogenous Leukemia > What Your Doctor is Reading About Acute Myelogenous Leukemia > General Interest Articles

General Interest Articles

1. Drug resistance in childhood acute myeloid leukemia.

Author: Styczynski J;
Institution: Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Bydgoszcz, Poland. jstyczynski@cm.umk.pl
Journal: Curr Pharm Biotechnol. 2007 Apr;8(2):59-75.
Abstract URL: Click here to view abstract

2. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission.

Author: Yanada M; Garcia-Manero G; Borthakur G; Ravandi F; Kantarjian H; Estey E;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. myanada@mdanderson.org
Journal: Cancer. 2007 Dec 15;110(12):2756-60.
Abstract URL: Click here to view abstract

3. Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia.

Author: Halim T; Song K; Barnett M; Forrest D; Hogge D; Nantel S; Nevill T; Shepherd J; Smith C; Sutherland H; Toze C; Lavoie J;
Institution: Department of Immunology and Microbiology, University of British Columbia, Vancouver.
Journal: Ann Oncol. 2007 Apr 17;.
Abstract URL: Click here to view abstract

4. Fetal Growth and Acute Childhood Leukemia: Looking Beyond Birth Weight.

Author: Milne E; Laurvick CL; Blair E; Bower C; de Klerk N;
Institution: Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australia.
Journal: Am J Epidemiol. 2007 Apr 18;.
Abstract URL: Click here to view abstract

5. A systematic review of myeloid leukemias and occupational pesticide exposure.

Author: Van Maele-Fabry G; Duhayon S; Lison D;
Institution: Unite de Toxicologie Industrielle et Medecine du travail, Universite Catholique de Louvain, Avenue E. Mounier 53, bte 5302, Brussels, 1200, Belgium, genevieve.vanmaele@toxi.ucl.ac.be.
Journal: Cancer Causes Control. 2007 Jun;18(5):457-78. Epub 2007 Apr 18.
Abstract URL: Click here to view abstract

6. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.

Author: Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E; Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E;
Institution
Journal: Br J Haematol. 2007 Aug;138(4):555-7. Epub 2007 Jun 25.

7. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century.

Author: Pulte D; Gondos A; Brenner H;
Institution: Div of Clinical Epidemiology & Aging Research, German Cancer Research Center, Bergheimer Str. 20, D-69115 Heidelberg, Germany.
Journal: Haematologica. 2008 Apr;93(4):594-600. Epub 2008 Mar 5.
Abstract URL: Click here to view abstract

8. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study.

Author: Mulrooney DA; Dover DC; Li S; Yasui Y; Ness KK; Mertens AC; Neglia JP; Sklar CA; Robison LL; Davies SM;
Institution: Department of Pediatrics, University of Minnesota Medical School and Cancer Center, Minneapolis, MN 55455, USA. mulro006@umn.edu
Journal: Cancer. 2008 May 1;112(9):2071-9.
Abstract URL: Click here to view abstract

9. Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit.

Author: Thakkar SG; Fu AZ; Sweetenham JW; Mciver ZA; Mohan SR; Ramsingh G; Advani AS; Sobecks R; Rybicki L; Kalaycio M; Sekeres MA;
Institution: Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA.
Journal: Cancer. 2008 May 15;112(10):2233-40.
Abstract URL: Click here to view abstract

10. Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Author: Fey M; Dreyling M;
Institution: Department of Medical Oncology, Inselspital and University of Bern, Bern, Switzerland.
Journal: Ann Oncol. 2008 May;19 Suppl 2:ii58-9.

11. Estimated number of cases, regional distribution and survival of patients diagnosed with acute myeloid leukemia between 1996 and 2000 in Rio Grande do Sul, Brazil.

Author: Capra M; Vilella L; Pereira WV; Coser VM; Fernandes MS; Schilling MA; Almeida D; Gross M; Leite M; Hellwig T; Natchigal G; Zelmanowicz A; Paskulin G; Neumann J; Silla L;
Institution: Division of Hematology and Bone Marrow Transplantation, Hospital de Clinicas de Porto Alegre, Programa de Pos-Graduacao em Clinica medica da Universidade Federal do Rio Grande do Sul. marcelocapra@hotmail.com
Journal: Leuk Lymphoma. 2007 Dec;48(12):2381-6.
Abstract URL: Click here to view abstract

12. Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA.

Author
Institution
Journal: Best Pract Res Clin Haematol. 2008 Mar;21(1):1-98.

13. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.

Author: Barbaric D; Alonzo TA; Gerbing RB; Meshinchi S; Heerema NA; Barnard DR; Lange BJ; Woods WG; Arceci RJ; Smith FO;
Institution: Division of Hematology/Oncology/BMT, BC's Children's Hospital, Vancouver, BC, Canada. dragmatt96@optusnet.com.au
Journal: Blood. 2007 Mar 15;109(6):2314-21. Epub 2006 Dec 7.
Abstract URL: Click here to view abstract

14. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

Author: Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C; Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C;
Institution: Biostatistics and Epidemiology Unit, Department of Medicine, , Institut Gustave-Roussy, Villejuif, France. le_deley@igr.fr
Journal: J Clin Oncol. 2007 Jan 20;25(3):292-300. Epub 2006 Dec 11.
Abstract URL: Click here to view abstract

15. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.

Author: Creutzig U; Diekamp S; Zimmermann M; Reinhardt D;
Institution: Department of Pediatric Hematology and Oncology, University Children's Hospital, Muenster, Germany.
Journal: Pediatr Blood Cancer. 2007 Jun 15;48(7):651-62.
Abstract URL: Click here to view abstract

16. Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213.

Author: Castellino SM; Alonzo TA; Buxton A; Gold S; Lange BJ; Woods WG; Castellino SM; Alonzo TA; Buxton A; Gold S; Lange BJ; Woods WG;
Institution: ETSU Quillen College of Medicine, Johnson City, Tennessee, USA. scastell@wfubmc.edu
Journal: Pediatr Blood Cancer. 2008 Jan;50(1):9-16.
Abstract URL: Click here to view abstract

17. Toxicity and outcome of children with treatment related acute myeloid leukemia.

Author: Tabori U; Revach G; Nathan PC; Strahm B; Rachlis A; Shago M; Grant R; Doyle J; Malkin D; Tabori U; Revach G; Nathan PC; Strahm B; Rachlis A; Shago M; Grant R; Doyle J; Malkin D;
Institution: Departments of Hematology Oncology and Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada.
Journal: Pediatr Blood Cancer. 2008 Jan;50(1):17-23.
Abstract URL: Click here to view abstract

18. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders.

Author: Hovi L; Saxen H; Saarinen-Pihkala UM; Vettenranta K; Meri T; Richardson M;
Institution: Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland. liisa.hovi@hus.fi
Journal: Pediatr Blood Cancer. 2007 Jan;48(1):28-34.
Abstract URL: Click here to view abstract

19. Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience.

Author: Rubnitz JE; Lensing S; Razzouk BI; Pounds S; Pui CH; Ribeiro RC;
Institution: Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. jeffrey.rubnitz@stjude.org
Journal: Pediatr Blood Cancer. 2007 Jan;48(1):10-5.
Abstract URL: Click here to view abstract

20. CXCR4 is a prognostic marker in acute myelogenous leukemia.

Author: Spoo AC; Lubbert M; Wierda WG; Burger JA;
Institution: Department of Medicine, Freiburg University Hospital, Germany.
Journal: Blood. 2007 Jan 15;109(2):786-91. Epub 2006 Aug 3.
Abstract URL: Click here to view abstract

21. Social support and survival in patients with acute myeloid leukaemia.

Author: Pinquart M; Hoffken K; Silbereisen RK; Wedding U;
Institution: Department of Developmental Psychology and Center for Applied Developmental Science, Friedrich Schiller University, 07743, Jena, Germany. Martin.Pinquart@uni-jena.de
Journal: Support Care Cancer. 2007 Jan;15(1):81-7. Epub 2006 Sep 27.
Abstract URL: Click here to view abstract

22. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia.

Author: Chowdhury M; Mihara K; Yasunaga S; Ohtaki M; Takihara Y; Kimura A;
Institution: 1Division of Clinical and Experimental Oncology, Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minami-Ku, Hiroshima, Japan.
Journal: Leukemia. 2007 May;21(5):1116-22. Epub 2007 Mar 22.

23. Novel therapeutic agents in acute myeloid leukemia.

Author: Stone RM;
Institution: Harvard Medical School and Leukemia Program, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA. rstone@partners.org
Journal: Exp Hematol. 2007 Apr;35(4 Suppl 1):163-6.
Abstract URL: Click here to view abstract

24. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.

Author: Meshinchi S; Arceci RJ;
Institution: Fred Hutchinson Cancer Research Center, University of Washington, Department of Pediatrics, Division of Clinical Research, Seattle, Washington, USA.
Journal: Oncologist. 2007 Mar;12(3):341-55.
Abstract URL: Click here to view abstract

25. Fatigue in older adults with acute myeloid leukemia: predictors and associations with quality of life and functional status.

Author: Alibhai SM; Leach M; Kowgier ME; Tomlinson GA; Brandwein JM; Minden MD;
Institution
Journal: Leukemia. 2007 Apr;21(4):845-8. Epub 2007 Feb 8.

26. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.

Author: Kim JS; Eom JI; Cheong JW; Choi AJ; Lee JK; Yang WI; Min YH;
Institution: Department of Internal Medicine, Brain Korea 21 Research Team of Nanobiomaterials for the Cell-Based Implants, Medical Research Center, Yonsei University College of Medicine, Seoul, Korea.
Journal: Clin Cancer Res. 2007 Feb 1;13(3):1019-28.
Abstract URL: Click here to view abstract

27. Monoclonal antibody-based therapeutics for leukemia.

Author: Li Y; Zhu Z; Li Y; Zhu Z;
Institution: Experimental Therapeutics, ImClone Systems, 180 Varick Street, New York, NY 10014, USA. yiwen.li@imclone.com
Journal: Expert Opin Biol Ther. 2007 Mar;7(3):319-30.
Abstract URL: Click here to view abstract

28. Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).

Author: Medeiros BC; Minden MD; Schuh AC; Schimmer AD; Yee K; Lipton JH; Messner HA; Gupta V; Chun K; Xu W; Das P; Kamel-Reid S; Brandwein JM;
Institution: Department of Medical Oncology, Peincess Margaret Hospital, University Health Network, Univeristy of Toronto, Toronto, Ontario, Canada.
Journal: Leuk Lymphoma. 2007 Jan;48(1):65-71.
Abstract URL: Click here to view abstract

29. Targeted agents in AML: much more to do.

Author: Stone RM;
Institution: Adult Leukemia Program, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, D 840 Boston, MA 02115, USA. rstone@partners.org
Journal: Best Pract Res Clin Haematol. 2007 Mar;20(1):39-48.
Abstract URL: Click here to view abstract

30. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

Author: Larson RA;
Institution: Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA. rlarson@medicine.bsd.uchicago.edu
Journal: Best Pract Res Clin Haematol. 2007 Mar;20(1):29-37.
Abstract URL: Click here to view abstract

31. Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation.

Author: Loh YS; Koh LP; Tai BC; Hwang WY; Linn YC; Goh YT; Tan PH;
Institution: Department of Haematology, Singapore General Hospital, Singapore. yvonne.loh.s.m@sgh.com.sg
Journal: Leuk Lymphoma. 2007 Jan;48(1):72-9.
Abstract URL: Click here to view abstract